




RealRate

PHARMACEUTICAL 2016

Acura Pharmaceuticals INC
Rank 195 of 295



The relative strengths and weaknesses of Acura Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acura Pharmaceuticals INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Acura Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 38% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	14,135
Cost of Goods Sold	0
Intangible Assets	1,638
Liabilities, Current	3,244
Liabilities, Non-Current	5,430
Other Assets	175
Other Compr. Net Income	-52
Other Expenses	986
Other Liabilities	387
Other Net Income	-988
Other Revenues	8,587
Property and Equipment	1,013
Research and Development	2,608
Selling, General and Administrative Expense	8,994

Output Variable	Value in 1000 USD
Assets	16,961
Liabilities	9,061
Expenses	12,588
Revenues	8,587
Stockholders Equity	7,900
Net Income	-4,989
Comprehensive Net Income	-5,015
BaseVar	24,118
ECR before LimitedLiability	94%
Economic Capital Ratio	225%